What is Mycoplasma genitalium?
Mycoplasma genitalium is a sexually transmitted bacterial pathogen that causes urethritis in men and cervicitis and pelvic inflammatory disease in women, representing an emerging cause of genital tract infections that often goes unrecognized in clinical practice.
Organism Characteristics
M. genitalium is the smallest self-replicating prokaryote capable of independent replication, belonging to the class Mollicutes 1, 2. First isolated in 1981 from men with urethritis, it lacks a cell wall and is extremely fastidious, making it nearly impossible to culture in routine clinical laboratories 1, 2.
Clinical Significance
In Men
- Acute and chronic non-gonococcal urethritis (NGU): M. genitalium is a well-established cause, with infections responding better to azithromycin than doxycycline 3, 4
- Persistent or recurrent urethritis: Should be considered when standard chlamydia/gonorrhea treatment fails 5
- Associated with balanoposthitis, chronic prostatitis, and acute epididymitis 5
In Women
- Cervicitis: Causes mucopurulent cervicitis similar to Chlamydia trachomatis 6, 7
- Pelvic inflammatory disease (PID): Strong evidence supports M. genitalium as a significant cause of upper tract inflammation 6
- Potential complications: Associated with infertility and adverse pregnancy outcomes 6, 5
Epidemiology
The organism is highly prevalent in both high-risk and general populations 6:
- High-risk populations (sexual health clinics): 7.3% prevalence
- Low-risk populations: 2.0% prevalence
- Prevalence rates fall between those of C. trachomatis and N. gonorrhoeae 6
Critical caveat: The majority of infected individuals remain asymptomatic and clear infection spontaneously without developing disease 1. This is why asymptomatic screening is not recommended 1, 8.
Transmission
M. genitalium is sexually transmitted 7, 9:
- Vaginal intercourse is the primary transmission route
- Anal intercourse in men who have sex with men is a common route of spread
- The organism can colonize ano-genital and oropharyngeal sites 9
Diagnosis
Major diagnostic challenge: M. genitalium cannot be cultured in routine clinical laboratories 1, 2. Diagnosis relies exclusively on molecular methods:
- Nucleic acid amplification tests (NAATs) are the only practical diagnostic approach 2
- Three FDA-approved tests are now available in the United States 8
- Testing should include detection of macrolide resistance mutations when available 1, 8
When to Test (per CDC guidelines) 8:
- Persistent male urethritis after standard treatment
- Cervicitis
- Proctitis
- Pelvic inflammatory disease (testing should be considered)
- Sexual contacts of patients with confirmed M. genitalium
When NOT to Test:
- Asymptomatic patients without exposure history
- Routine screening in pregnant women (unless exposure documented) 8
Treatment Challenges
Critical concern: Widespread antimicrobial resistance has emerged due to syndromic management without specific testing 1:
- Macrolide resistance is increasingly common and correlates with treatment failure 2
- Few antimicrobial classes have activity against M. genitalium
- Significant concern exists regarding emergence of untreatable strains 1
The CDC recommends 2-step treatment with doxycycline followed by azithromycin or moxifloxacin, with moxifloxacin preferred when resistance testing is unavailable or demonstrates macrolide resistance 8.
Clinical Recognition
Historically, M. genitalium was not mentioned in earlier CDC STD treatment guidelines 10, 11, reflecting its status as an emerging pathogen. By 2006-2010, guidelines began acknowledging that M. genitalium infections may respond better to azithromycin than doxycycline 3, 4. Current recognition as documented in the 2018 IDSA/ASM guidelines identifies M. genitalium as a cause of nongonococcal urethritis in males and cervicitis and PID in females 12.
Key clinical pitfall: Because M. genitalium behaves similarly to C. trachomatis but requires different treatment considerations, clinicians must maintain high suspicion in cases of persistent urethritis or cervicitis despite standard chlamydia/gonorrhea treatment 7.